AstraZeneca and Janssen to jointly promote prostate cancer treatment in Japan
UK-based drugmaker AstraZeneca and Janssen Pharmaceuticals K.K have entered into a co-promotion agreement for a new oral therapy called abiraterone acetate, a CYP17-inhibitor, to treat prostate cancer patients. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 14, 2013 Category: Pharmaceuticals Source Type: news
Evidence for Improved Patient Quality of Life With Prostate Cancer Drug
Abiraterone acetate in combination with prednisone delays pain progression as well as health-related quality of life compared with prednisone alone in prostate cancer patients, a new study shows. (Source: Cancer Network)
Source: Cancer Network - September 30, 2013 Category: Cancer & Oncology Source Type: news
Abiraterone acetate delays quality of life decline in men with metastatic prostate cancer
(University of North Carolina Health Care) Abiraterone acetate, a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer, significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 24, 2013 Category: Cancer & Oncology Source Type: news
Does Abiraterone Offer An Added Benefit Compared With The Present Standard Therapy For Metastatic Prostate Cancer?
Certain men with metastatic prostate cancer have advantages in comparison with watchful waiting Abiraterone acetate (abiraterone for short, trade name: Zytiga) has been approved in Germany since December 2012 for men with metastatic prostate cancer that is not responsive to hormone blockade, who only have mild symptoms or so far none at all, and in whom chemotherapy is not yet indicated... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 5, 2013 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news
Zytiga (abiraterone acetate) - Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Developed by Coughar Biotechnology, abiraterone acetate (CB7630) was discovered by the UK Institute for Cancer Research. (Source: Drug Development Technology)
Source: Drug Development Technology - April 29, 2013 Category: Pharmaceuticals Source Type: news
Zytiga Prolongs Prostate Cancer Survival
ORLANDO (MedPage Today) -- Survival improved and disease progression slowed in men with metastatic castration-resistant prostate cancer treated in first line with abiraterone acetate (Zytiga). (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 17, 2013 Category: Hematology Source Type: news
Follow-up Data Show ZYTIGA? Plus Prednisone Continues to Delay Progression of Metastatic Castration-Resistant Prostate Cancer in Patients without Prior Chemotherapy(Feb 12, 2013)
Orlando, Fla., February 12, 2013 ? Janssen Research & Development, LLC [Janssen] announced today that updated results showing ZYTIGA? (abiraterone acetate) plus prednisone continued to provide statistically significant improvements in disease progression compared to placebo plus prednisone, and longer overall survival in men with metastatic castration-resistant prostate cancer..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - February 12, 2013 Category: Pharmaceuticals Source Type: news
Follow-up Data Show ZYTIGA® Plus Prednisone Continues to Delay Progression of Metastatic Castration-Resistant Prostate Cancer in Patients without Prior Chemotherapy(Feb 12, 2013)
Orlando, Fla., February 12, 2013 – Janssen Research & Development, LLC [Janssen] announced today that updated results showing ZYTIGA® (abiraterone acetate) plus prednisone continued to provide statistically significant improvements in disease progression compared to placebo plus prednisone, and longer overall survival in men with metastatic castration-resistant prostate cancer..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - February 12, 2013 Category: Pharmaceuticals Source Type: news
ZYTIGA® approved in the EU
Janssen-Cilag International NV (Janssen) has announced that the European Commission (EC) has approved an extension to the license of the oral, once-daily medication ZYTIGA® (abiraterone acetate). (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 15, 2013 Category: Drugs & Pharmacology Source Type: news
European Commission clears extended licence to JanssenZytiga
Janssen-Cilag International NV (Janssen) has announced European Commission approval of an extended licence to the oral, once-daily medication Zytiga (abiraterone acetate). (Source: Drug Development Technology)
Source: Drug Development Technology - January 15, 2013 Category: Pharmaceuticals Source Type: news
Addition of abiraterone acetate to prednisone improved fatigue in patients with prostate cancer
Sternberg CN. Ann Oncol. 2012;doi:10.1093/annonc/mds585. (Source: HemOncToday.com)
Source: HemOncToday.com - January 3, 2013 Category: Cancer & Oncology Source Type: news
